Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study
暂无分享,去创建一个
T. Friede | M. Addo | T. Rauen | O. Moerer | S. Huber | S. Blaschke | O. Gross | W. Windisch | M. Dreher | S. Kluge | J. Turner | J. Floege | C. Schmidt-Lauber | T. Huber | S. Scheithauer | A. Jörres | E. Hoxha | G. Braun | A. Elfanish | Jan Böckhaus | M. Kamm
[1] U. Janssens,et al. Clinical practice guideline: Recommendations on in-hospital treatment of patients with COVID-19 , 2021 .
[2] A. Vijayan,et al. SARS-CoV-2 in the kidney: bystander or culprit? , 2020, Nature Reviews Nephrology.
[3] C. Seymour. A cooperation of the doves , 2020, Intensive Care Medicine.
[4] Victor G. Puelles,et al. SARS-CoV-2 renal tropism associates with acute kidney injury , 2020, The Lancet.
[5] R. Busse,et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study , 2020, The Lancet Respiratory Medicine.
[6] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[7] M. Aepfelbacher,et al. Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.
[8] Axel Haverich,et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.
[9] Victor G. Puelles,et al. Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.
[10] O. Moerer,et al. COVID-19-associated nephritis: early warning for disease severity and complications? , 2020, The Lancet.
[11] G. Remuzzi,et al. Adaptations and Lessons in the Province of Bergamo , 2020, The New England journal of medicine.
[12] P. Welling,et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. , 2020, Journal of the American Society of Nephrology : JASN.
[13] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[14] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[15] Ying Yao,et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. , 2020, Journal of the American Society of Nephrology : JASN.
[16] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[17] Holger Moch,et al. Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.
[18] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[19] Hongliang Li,et al. The Science Underlying COVID-19: Implications for the Cardiovascular System. , 2020, Circulation.
[20] G. Heinze,et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal , 2020, BMJ.
[21] Yan Peng,et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.
[22] Dengju Li,et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.
[23] A. Davis,et al. Management of Critically Ill Adults With COVID-19. , 2020, JAMA.
[24] Ezekiel J Emanuel,et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. , 2020, The New England journal of medicine.
[25] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[26] Yi Yang,et al. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province , 2020, Annals of Intensive Care.
[27] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[28] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[29] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[30] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[31] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[32] R. Balk,et al. Role of Antithrombin III and Tissue Factor Pathway in the Pathogenesis of Sepsis. , 2020, Critical care clinics.
[33] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[34] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[35] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[36] Richard D Riley,et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal , 2020 .
[37] M. Chandra. Idiopathic nephrotic syndrome in children , 1982 .